Cancer Immunotherapy Drug Discovery Outsourcing Market Growth and Profit Analysis, Forecast by 2030

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Cancer Immunotherapy Drug Discovery Outsourcing Market Size Analysis

Global Cancer Immunotherapy Drug Discovery Outsourcing Market Introduction
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Monoclonal Antibodies
  1. By Value
3. Immunomodulators
  1. By Value
4. Oncolytic Viral Therapies and Cancer Vaccines
  1. By Value
5. Others
  1. By Value
By Service Type
1. Introduction
  1. Service Type By Value
2. Target Identification and Validation
  1. By Value
3. Lead Screening and Characterization
  1. By Value
4. Cell-Based Assays
  1. By Value
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Lung
  1. By Value
3. Breast
  1. By Value
4. Colorectal
  1. By Value
5. Melanoma
  1. By Value
6. Prostate
  1. By Value
7. Pancreatic
  1. By Value
8. Head and Neck
  1. By Value
9. Ovarian
  1. By Value

North America Market Analysis

Introduction
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Monoclonal Antibodies
  1. By Value
3. Immunomodulators
  1. By Value
4. Oncolytic Viral Therapies and Cancer Vaccines
  1. By Value
5. Others
  1. By Value
By Service Type
1. Introduction
  1. Service Type By Value
2. Target Identification and Validation
  1. By Value
3. Lead Screening and Characterization
  1. By Value
4. Cell-Based Assays
  1. By Value
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Lung
  1. By Value
3. Breast
  1. By Value
4. Colorectal
  1. By Value
5. Melanoma
  1. By Value
6. Prostate
  1. By Value
7. Pancreatic
  1. By Value
8. Head and Neck
  1. By Value
9. Ovarian
  1. By Value
U.S.
1. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Monoclonal Antibodies
    1. By Value
  3. Immunomodulators
    1. By Value
  4. Oncolytic Viral Therapies and Cancer Vaccines
    1. By Value
  5. Others
    1. By Value
2. By Service Type
  1. Introduction
    1. Service Type By Value
  2. Target Identification and Validation
    1. By Value
  3. Lead Screening and Characterization
    1. By Value
  4. Cell-Based Assays
    1. By Value
3. By Cancer Type
  1. Introduction
    1. Cancer Type By Value
  2. Lung
    1. By Value
  3. Breast
    1. By Value
  4. Colorectal
    1. By Value
  5. Melanoma
    1. By Value
  6. Prostate
    1. By Value
  7. Pancreatic
    1. By Value
  8. Head and Neck
    1. By Value
  9. Ovarian
    1. By Value
Canada

Europe Market Analysis

Introduction
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Monoclonal Antibodies
  1. By Value
3. Immunomodulators
  1. By Value
4. Oncolytic Viral Therapies and Cancer Vaccines
  1. By Value
5. Others
  1. By Value
By Service Type
1. Introduction
  1. Service Type By Value
2. Target Identification and Validation
  1. By Value
3. Lead Screening and Characterization
  1. By Value
4. Cell-Based Assays
  1. By Value
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Lung
  1. By Value
3. Breast
  1. By Value
4. Colorectal
  1. By Value
5. Melanoma
  1. By Value
6. Prostate
  1. By Value
7. Pancreatic
  1. By Value
8. Head and Neck
  1. By Value
9. Ovarian
  1. By Value
U.K.
1. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Monoclonal Antibodies
    1. By Value
  3. Immunomodulators
    1. By Value
  4. Oncolytic Viral Therapies and Cancer Vaccines
    1. By Value
  5. Others
    1. By Value
2. By Service Type
  1. Introduction
    1. Service Type By Value
  2. Target Identification and Validation
    1. By Value
  3. Lead Screening and Characterization
    1. By Value
  4. Cell-Based Assays
    1. By Value
3. By Cancer Type
  1. Introduction
    1. Cancer Type By Value
  2. Lung
    1. By Value
  3. Breast
    1. By Value
  4. Colorectal
    1. By Value
  5. Melanoma
    1. By Value
  6. Prostate
    1. By Value
  7. Pancreatic
    1. By Value
  8. Head and Neck
    1. By Value
  9. Ovarian
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Monoclonal Antibodies
  1. By Value
3. Immunomodulators
  1. By Value
4. Oncolytic Viral Therapies and Cancer Vaccines
  1. By Value
5. Others
  1. By Value
By Service Type
1. Introduction
  1. Service Type By Value
2. Target Identification and Validation
  1. By Value
3. Lead Screening and Characterization
  1. By Value
4. Cell-Based Assays
  1. By Value
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Lung
  1. By Value
3. Breast
  1. By Value
4. Colorectal
  1. By Value
5. Melanoma
  1. By Value
6. Prostate
  1. By Value
7. Pancreatic
  1. By Value
8. Head and Neck
  1. By Value
9. Ovarian
  1. By Value
China
1. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Monoclonal Antibodies
    1. By Value
  3. Immunomodulators
    1. By Value
  4. Oncolytic Viral Therapies and Cancer Vaccines
    1. By Value
  5. Others
    1. By Value
2. By Service Type
  1. Introduction
    1. Service Type By Value
  2. Target Identification and Validation
    1. By Value
  3. Lead Screening and Characterization
    1. By Value
  4. Cell-Based Assays
    1. By Value
3. By Cancer Type
  1. Introduction
    1. Cancer Type By Value
  2. Lung
    1. By Value
  3. Breast
    1. By Value
  4. Colorectal
    1. By Value
  5. Melanoma
    1. By Value
  6. Prostate
    1. By Value
  7. Pancreatic
    1. By Value
  8. Head and Neck
    1. By Value
  9. Ovarian
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Monoclonal Antibodies
  1. By Value
3. Immunomodulators
  1. By Value
4. Oncolytic Viral Therapies and Cancer Vaccines
  1. By Value
5. Others
  1. By Value
By Service Type
1. Introduction
  1. Service Type By Value
2. Target Identification and Validation
  1. By Value
3. Lead Screening and Characterization
  1. By Value
4. Cell-Based Assays
  1. By Value
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Lung
  1. By Value
3. Breast
  1. By Value
4. Colorectal
  1. By Value
5. Melanoma
  1. By Value
6. Prostate
  1. By Value
7. Pancreatic
  1. By Value
8. Head and Neck
  1. By Value
9. Ovarian
  1. By Value
UAE
1. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Monoclonal Antibodies
    1. By Value
  3. Immunomodulators
    1. By Value
  4. Oncolytic Viral Therapies and Cancer Vaccines
    1. By Value
  5. Others
    1. By Value
2. By Service Type
  1. Introduction
    1. Service Type By Value
  2. Target Identification and Validation
    1. By Value
  3. Lead Screening and Characterization
    1. By Value
  4. Cell-Based Assays
    1. By Value
3. By Cancer Type
  1. Introduction
    1. Cancer Type By Value
  2. Lung
    1. By Value
  3. Breast
    1. By Value
  4. Colorectal
    1. By Value
  5. Melanoma
    1. By Value
  6. Prostate
    1. By Value
  7. Pancreatic
    1. By Value
  8. Head and Neck
    1. By Value
  9. Ovarian
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Monoclonal Antibodies
  1. By Value
3. Immunomodulators
  1. By Value
4. Oncolytic Viral Therapies and Cancer Vaccines
  1. By Value
5. Others
  1. By Value
By Service Type
1. Introduction
  1. Service Type By Value
2. Target Identification and Validation
  1. By Value
3. Lead Screening and Characterization
  1. By Value
4. Cell-Based Assays
  1. By Value
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Lung
  1. By Value
3. Breast
  1. By Value
4. Colorectal
  1. By Value
5. Melanoma
  1. By Value
6. Prostate
  1. By Value
7. Pancreatic
  1. By Value
8. Head and Neck
  1. By Value
9. Ovarian
  1. By Value
Brazil
1. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Monoclonal Antibodies
    1. By Value
  3. Immunomodulators
    1. By Value
  4. Oncolytic Viral Therapies and Cancer Vaccines
    1. By Value
  5. Others
    1. By Value
2. By Service Type
  1. Introduction
    1. Service Type By Value
  2. Target Identification and Validation
    1. By Value
  3. Lead Screening and Characterization
    1. By Value
  4. Cell-Based Assays
    1. By Value
3. By Cancer Type
  1. Introduction
    1. Cancer Type By Value
  2. Lung
    1. By Value
  3. Breast
    1. By Value
  4. Colorectal
    1. By Value
  5. Melanoma
    1. By Value
  6. Prostate
    1. By Value
  7. Pancreatic
    1. By Value
  8. Head and Neck
    1. By Value
  9. Ovarian
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Cancer Immunotherapy Drug Discovery Outsourcing Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Aquila Biomedical
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Covance, Inc.
Crown Bioscience Inc.
BPS Biosciences Inc.
Horizon Discovery Group PLC
Explicit Immuno-Oncology
Gen script Biotech Corporation
ImmunXperts SA
Promega Corporation
STC Biologics
Molecular Imaging Inc. (MI Bioresearch Inc.)
Celentyx Ltd.
DiscoverX Corporation
HD Biosciences Co. Ltd.
Personalis, Inc.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment